Blair William & Co. IL cut its stake in shares of Phreesia, Inc. (NYSE:PHR – Free Report) by 3.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 725,500 shares of the company’s stock after selling 27,200 shares during the quarter. Blair William & Co. IL owned approximately 1.26% of Phreesia worth $15,381,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in shares of Phreesia by 5,462.3% during the fourth quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after purchasing an additional 3,769 shares during the period. Private Advisor Group LLC bought a new stake in Phreesia in the fourth quarter worth about $263,000. Charles Schwab Investment Management Inc. lifted its stake in Phreesia by 3.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 412,763 shares of the company’s stock valued at $9,555,000 after purchasing an additional 15,298 shares during the last quarter. Norges Bank purchased a new position in shares of Phreesia during the 4th quarter valued at $8,199,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in Phreesia during the fourth quarter worth about $357,000. 92.10% of the stock is owned by institutional investors and hedge funds.
Phreesia Price Performance
Shares of PHR stock opened at $23.75 on Friday. The stock has a 50 day moving average price of $24.05 and a 200 day moving average price of $22.73. Phreesia, Inc. has a 52-week low of $12.05 and a 52-week high of $29.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.77 and a current ratio of 1.77. The firm has a market capitalization of $1.36 billion, a P/E ratio of -10.94 and a beta of 0.93.
Analysts Set New Price Targets
Insider Transactions at Phreesia
In other news, General Counsel Allison C. Hoffman sold 2,622 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total value of $60,961.50. Following the transaction, the general counsel now directly owns 123,075 shares in the company, valued at $2,861,493.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Phreesia news, COO Evan Roberts sold 1,669 shares of Phreesia stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total transaction of $39,622.06. Following the completion of the sale, the chief operating officer now directly owns 753,234 shares of the company’s stock, valued at approximately $17,881,775.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Allison C. Hoffman sold 2,622 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $60,961.50. Following the transaction, the general counsel now directly owns 123,075 shares in the company, valued at approximately $2,861,493.75. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 46,179 shares of company stock worth $1,129,122. 5.80% of the stock is currently owned by insiders.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Featured Articles
- Five stocks we like better than Phreesia
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR – Free Report).
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.